Keybanc analyst Adam Josephson maintains WestRock (NYSE:WRK) with a Underweight and lowers the price target from $44 to $36.
Insmed Earlier Reported Q2 EPS $(0.80) Beats $(0.89) Estimate, Sales $65.22M Beat $59.41M Estimate
Insmed (NASDAQ:INSM) reported quarterly losses of $(0.80) per share which beat the analyst consensus estimate of $(0.89) by 10.11 percent. This is a 12.09 percent increase over losses of $(0.91) per share from the same
